AKESO(HK:09926) Ge Long Hui·2025-08-12 15:09Core Viewpoint - The report from Huafu Securities indicates that Kangfang Biopharma (9926.HK) is leading globally in the development of its self-researched dual antibody AK112, which is expected to capture the largest share of the global second-generation immuno-oncology (IO) market [1] Financial Projections - The projected revenues for Kangfang Biopharma for the years 2025, 2026, and 2027 are estimated to be 35.18 billion, 57.65 billion, and 93.72 billion CNY respectively [1] - The expected net profits attributable to the parent company for the same years are projected to be -1.86 billion, 8.03 billion, and 29.66 billion CNY respectively [1] Valuation - The reasonable market capitalization for Kangfang Biopharma is estimated to be 222.8 billion HKD [1] - The report maintains a "buy" rating for the company's stock [1]